Tags : License Agreement

Astellas Signs a License Agreement with Welldoc to Develop and

Shots: Welldoc to receive $15M upfront, development & commercialization milestones and royalties on sales. Astellas and Welldoc will jointly develop and commercialize BlueStar for patients with diabetes in Asian countries including Japan The companies will co-develop & co-commercialize digital therapies globally for multiple therapeutic areas. The collaboration allows Welldoc to widen its platform in other […]Read More

Sarepta Signs a License Agreement with Stride Bio to Develop

Shots: The companies collaborated to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets. StrideBio will be responsible for research, development and manufacturing of the first four CNS targets which include MECP2 (Rett syndrome), SCN1A (Dravet syndrome), UBE3A (Angelman syndrome), and NPC1 (Niemann-Pick) Stride Bio to receive $48M upfront […]Read More

Allergan Signs an Exclusive Option and License Agreement with Exicure

Shots: Exicure to receive $25M upfront, up to $97.5/program development & regulatory milestones, ~$265/program commercial milestones, royalties on global sales of therapies developed under the collaboration and will conduct discovery and development in two programs for hair loss disorders like androgenetic alopecia Allergan to get exclusive access and options to license SNA-based therapies developed under […]Read More

Zambon Signs a License Agreement with Aquestive to Develop and

Shots: Aquestive to receive up front, development & commercial milestones and royalties on sales of Riluzole oral film (ROF) in EU. Zambon to get a license for the development and commercialization of ROF to treat ALS in EU Zambon will be responsible for the regulatory approval and marketing of ROF in the EU while Aquestive […]Read More

Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE

Shots: UBE to receive up front, development & commercial milestones and royalties on sales. Novo Nordisk to get exclusive WW license to UBE’s preclinical asset UD-014 and will be responsible for development, manufacturing and commercialization of UD-014 The collaboration will widen Novo Nordisk’s presence and investment in NASH and will provide more treatment options to […]Read More

Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar

Shots: Bioeq to receive up front, regulatory and launch milestones with equal profit sharing. Coherus to get exclusive rights to commercialize biosimilar candidate referencing Genentech’s Lucentis with its anticipated launch in 2021 in the US Bioeq will be responsible for product delivery to the Coherus and will submit BLA to the US FDA in Q4’19 […]Read More

Astellas Signs an Exclusive License Agreement with Pandion to Deliver

Shots: Pandion to receive up to $45M as upfront and payments for research and preclinical activities, ~$750M as development and commercial milestone and royalties on global sales of the therapies developed via collaboration Pandion to be responsible for drug designing and discovery of bispecific therapies utilizing its modular immune effector and tissue tether platform while […]Read More

Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop

Shots: Blueprint to receive $535M including $25M up front and up to $510M as development, regulatory & commercial milestone for BLU-782 in up to two indications, including FOP with royalties on global sales of BLU-782 The collaboration robust Ipsen’s rare diseases portfolio and accelerates Blueprint’s aim to globally develop BLU-782 by utilizing Ipsen’s clinical expertise […]Read More

Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for

Shots: Akcea and Ionis to receive $250M, up to $1.3B as development, regulatory and commercial milestone with royalties on global sales of AKCEA-ANGPTL3-L(Rx) splitting equally b/w the companies. Akcea will settle its $125M obligations to Ionis in Akcea common stock Pfizer will be responsible for all development and regulatory activities and costs after P-II study. […]Read More